rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Nexentis Technologies Inc.

NXTS · Nasdaq

Health CareBiotechnologyNot moving yet

NXTS stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 81.5% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
18% -14 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$345
Officials’ trades on record
0
Institutions holding
5 (-4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

21 Apr – 20 Oct
18%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$333$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months1
Buyers · sellers0 · 1
WhoDidSharesTraded
Eun Young Lee10% ownersold127at $1.3629 Jan 2026filed 26 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders5-4 on the quarter
New · exited1 · 5
Reported value$78K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Yorkville Advisors Global, LPunchanged · filed 6 Aug 202616,409$71K00.0%
VANGUARD FIDUCIARY TRUST COreduced · filed 13 Aug 2026998$4,301-5,989−85.7%
Tower Research Capital LLC (TRC)reduced · filed 11 Aug 2026736$3,172-3,766−83.7%
SBI Securities Co., Ltd.reduced · filed 23 Jul 202632$138-26−44.8%
BARCLAYS PLCnew · filed 14 Aug 20261$4+1
30 Sep 2025 – 30 Jun 2026
579Sep 25Dec 25Mar 26Jun 26

Everyone who traded it

Amitay Weiss Company insiderDirector · last 15 Oct 20261 · 0
David Palach Company insiderChief Executive Officer · last 15 Oct 20260 · 0
Eliahou Arbib Company insiderDirector · last 15 Oct 20261 · 0
Israel Yakov Berenstein Company insiderDirector · last 15 Oct 20261 · 0
Liat Sidi Company insiderDirector · last 15 Oct 20260 · 0
Lital Barda Company insiderChief Financial Officer · last 15 Oct 20260 · 0
Ronen Rosenbloom Company insiderDirector · last 15 Oct 20262 · 0
Shlomo Zakai Company insiderController · last 15 Oct 20260 · 0
Eun Young Lee Company insider10% owner · last 29 Jan 20260 · 1
Asaf Itzhaik Company insiderDirector · last 23 Dec 20240 · 0
Udi Ovadia Kalifi Company insiderDirector · last 23 Dec 20243 · 0
Benad Goldwasser Company insiderDirector · last 24 Sep 20200 · 0

Same industry

MRNA ModernaLeading+167%
ENTX Entera BioLeading+52%
XNCR XencorLeading+41%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-22.3%
Debt to equityFY 2025 · to 31 Dec 20250.09×
Share count trendFY 2025 · to 31 Mar 202684.3%
Cash and equivalentsFY 2025 · to 31 Dec 2025$3.8M
Free cash flowFY 2025 · to 31 Dec 2025−$3.8M

Analyst forecasts

No analyst forecasts yet.